Bristol-Myers Squibb (BMY) stock slips despite earnings beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank
April 29, 2024 5:27 AM EDTDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
April 25, 2024 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of ($4.40), $0.07 better than the analyst estimate of ($4.47). Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
... More